Mersana Therapeutics (MRSN) News Today → What’s Really Next for America… (From Porter & Company) (Ad) Free MRSN Stock Alerts $2.62 -0.09 (-3.32%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12 at 8:13 PM | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMay 11 at 12:16 AM | marketbeat.comMersana Therapeutics (NASDAQ:MRSN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPSMersana Therapeutics (NASDAQ:MRSN - Get Free Report) announced its earnings results on Thursday. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. Mersana Therapeutics had a negative net margin of 465.80% and a negative return on equity of 282.36%. The business had revenue of $9.25 million during the quarter, compared to the consensus estimate of $8.50 million. During the same quarter in the previous year, the firm posted ($0.52) EPS. Mersana Therapeutics's revenue was up 18.5% compared to the same quarter last year.May 10, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comMersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed AnalysisMay 10, 2024 | americanbankingnews.comStock Traders Buy High Volume of Call Options on Mersana Therapeutics (NASDAQ:MRSN)May 9, 2024 | investorplace.comMRSN Stock Earnings: Mersana Therapeutics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | marketbeat.comMersana Therapeutics Sees Unusually Large Options Volume (NASDAQ:MRSN)Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) saw unusually large options trading on Thursday. Traders bought 8,320 call options on the company. This is an increase of 1,954% compared to the typical daily volume of 405 call options.May 9, 2024 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comMersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsMay 8, 2024 | americanbankingnews.comMersana Therapeutics (MRSN) Scheduled to Post Earnings on ThursdayMay 3, 2024 | globenewswire.comMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | marketbeat.comMersana Therapeutics (MRSN) to Release Quarterly Earnings on ThursdayMersana Therapeutics (NASDAQ:MRSN) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 2, 2024 | globenewswire.comMersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024April 20, 2024 | seekingalpha.comMRSN Mersana Therapeutics, Inc.April 18, 2024 | marketbeat.comReadystate Asset Management LP Makes New Investment in Mersana Therapeutics, Inc. (NASDAQ:MRSN)Readystate Asset Management LP acquired a new position in Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 295,038 shares of the coApril 5, 2024 | morningstar.comMersana Therapeutics Inc MRSNApril 4, 2024 | globenewswire.comMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Short Interest Up 22.3% in MarchMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 8,730,000 shares, an increase of 22.3% from the February 29th total of 7,140,000 shares. Based on an average daily volume of 2,290,000 shares, the short-interest ratio is presently 3.8 days.April 1, 2024 | marketbeat.comMersana Therapeutics (NASDAQ:MRSN) Stock Price Down 6%Mersana Therapeutics (NASDAQ:MRSN) Trading Down 6%March 20, 2024 | marketbeat.comMersana Therapeutics (NASDAQ:MRSN) Stock Price Down 3.2%Mersana Therapeutics (NASDAQ:MRSN) Shares Down 3.2%March 19, 2024 | markets.businessinsider.comThe Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 ExpertsMarch 19, 2024 | marketbeat.comMersana Therapeutics (NASDAQ:MRSN) Shares Gap Up to $4.86Mersana Therapeutics (NASDAQ:MRSN) Shares Gap Up to $4.86March 19, 2024 | marketbeat.comMersana Therapeutics (NASDAQ:MRSN) Raised to Neutral at JPMorgan Chase & Co.JPMorgan Chase & Co. upgraded Mersana Therapeutics from an "underweight" rating to a "neutral" rating and set a $5.00 price objective for the company in a research report on Tuesday.March 17, 2024 | marketbeat.comWalleye Capital LLC Has $2.57 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN)Walleye Capital LLC raised its holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 1,205.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,021,467 shares of the company's stock after buying an additional 1,866,568 sharMarch 14, 2024 | marketbeat.comMersana Therapeutics (NASDAQ:MRSN) Shares Down 6.4% Mersana Therapeutics (NASDAQ:MRSN) Shares Down 6.4%March 3, 2024 | marketbeat.comMersana Therapeutics (NASDAQ:MRSN) Trading 6.3% Higher Following Analyst UpgradeMersana Therapeutics (NASDAQ:MRSN) Stock Price Up 6.3% on Analyst UpgradeMarch 2, 2024 | marketbeat.comAffinity Asset Advisors LLC Invests $3.62 Million in Mersana Therapeutics, Inc. (NASDAQ:MRSN)Affinity Asset Advisors LLC acquired a new position in Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm acquired 2,850,000 shares of the company's stock, valued at approximately $3,620,000. Mersana TherapeutiMarch 1, 2024 | seekingalpha.comMersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | nasdaq.comGuggenheim Upgrades Mersana Therapeutics (MRSN)March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mersana Therapeutics Amid Promising ADC Developments and Upcoming MilestonesMarch 1, 2024 | msn.comTruist Securities Upgrades Mersana Therapeutics (MRSN)March 1, 2024 | msn.comWedbush Upgrades Mersana Therapeutics (MRSN)March 1, 2024 | marketbeat.comMersana Therapeutics (NASDAQ:MRSN) Shares Up 6.3% After Analyst UpgradeMersana Therapeutics (NASDAQ:MRSN) Trading Up 6.3% on Analyst UpgradeMarch 1, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Expected to Earn Q1 2025 Earnings of ($0.23) Per ShareMersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Equities research analysts at Wedbush issued their Q1 2025 earnings estimates for Mersana Therapeutics in a research note issued on Thursday, February 29th. Wedbush analyst D. Nierengarten expects that the company will earn ($0.23) per sharFebruary 29, 2024 | markets.businessinsider.comExpert Outlook: Mersana Therapeutics Through The Eyes Of 5 AnalystsFebruary 29, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | marketbeat.comTruist Financial Upgrades Mersana Therapeutics (NASDAQ:MRSN) to BuyTruist Financial upgraded Mersana Therapeutics from a "hold" rating to a "buy" rating and set a $9.00 price objective for the company in a research note on Thursday.February 29, 2024 | marketbeat.comRobert W. Baird Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $5.00Robert W. Baird upped their price objective on Mersana Therapeutics from $1.00 to $5.00 and gave the company a "neutral" rating in a research note on Thursday.February 29, 2024 | realmoney.thestreet.comGuggenheim gets more bullish on Mersana Therapeutics, upgrades sharesFebruary 29, 2024 | finance.yahoo.comMersana Therapeutics Full Year 2023 Earnings: Revenues DisappointFebruary 29, 2024 | finance.yahoo.comAn Intrinsic Calculation For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Suggests It's 26% UndervaluedFebruary 29, 2024 | finance.yahoo.comQ4 2023 Mersana Therapeutics Inc Earnings CallFebruary 28, 2024 | finanznachrichten.deMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | msn.comMersana Therapeutics GAAP EPS of -$0.16 in-line, revenue of $10.7M misses by $4.07MFebruary 28, 2024 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | finance.yahoo.comMersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | globenewswire.comMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | markets.businessinsider.comHere's what Wall Street expects from Mersana Therapeutics's earningsFebruary 27, 2024 | msn.comMersana Therapeutics Q4 2023 Earnings PreviewFebruary 27, 2024 | globenewswire.comMersana Therapeutics to Present at Upcoming Investor Conferences Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Millionaire investor and Republican donor makes surprising election prediction (Ad)Find out who Louis believes is going to win the election... And why that will launch a second boom in AI stocks Click for his six specific AI stock in the crosshairs MRSN Media Mentions By Week MRSN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRSN News Sentiment▼0.500.57▲Average Medical News Sentiment MRSN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRSN Articles This Week▼132▲MRSN Articles Average Week Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ANNX News Today BMEA News Today HRTX News Today KRRO News Today LXRX News Today NGNE News Today CRBP News Today ESPR News Today ANRO News Today PEPG News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRSN) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityThe only AI company you should be looking atBehind the MarketsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
